Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars
Firm Concedes That Adoption Of Adalimumab Rivals ‘Has Not Reached Anticipated Potential’
• By David Wallace
Boehringer has cut sales staff for its Humira biosimilar • Source: Shutterstock 
